NEWS
Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
Silo Pharma (NASDAQ: SILO) has partnered with Resyca BV for the Device and CMC Development Master Plan of SPC-15, an intranasal PTSD treatment.
This collaboration aims to support IND-enabling studies for SPC-15, which utilizes a patented nasal spray system for nose-to-brain drug delivery.
The technology is expected to increase drug concentration in the brain, potentially offering faster therapeutic benefits and improved safety for PTSD patients.
Silo holds exclusive rights to Medspray's spray mist technology for multiple indications, including PTSD.
The company is currently conducting GLP-compliant pharmacokinetic and pharmacodynamic studies and has submitted a pre-IND briefing package to the FDA. These steps are important for the eventual submission of an IND application, with the goal of initiating the first human clinical trial for SPC-15.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1076Followers
68Following
7401Visitors
Follow